Latest news and press releases about Oncolytics Biotech Inc. (ONCY): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer.
Price
| Price | $0.77 |
| Market Cap | $77M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | -20.69 |
| EV / EBITDA | -2.98 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 1020.21% |
| Return on Invested Capital | -1480.50% |
| Return on Assets | -498.10% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ATOS · CLNN · COYA · IMMX · MGNX · SRZN · TIL
Explore sector: Healthcare · Biotechnology
More sections of ONCY: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks